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Western Blot. Prostaglandin E2 (PGE2) and metalloproteinase-13 (MMP-
13) levels as well as glutathione S-transferase (GST) activity were
each assessed with commercial kits. NO release was determined using
improved Griess method. Reactive oxygen species (ROS) generation was
revealed using ﬂuorescent microscopy with the use of commercial kits.
Results: L-NIL prevented IL-1b-induced NO release, iNOS expression at
protein and mRNA levels, S-nitrosylated proteins and HNE in a dose
dependent manner after 24h of incubation. Interestingly, we revealed
that L-NIL abolished IL-1b-induced NOX component p47phox. The HNE-
induced PGE2 release and both cyclooxygenase-2 (COX-2) and MMP-13
expression were signiﬁcantly reduced by L-NIL addition. Furthermore,
L-NIL blocked the IL-1b induced inactivation of GST, an HNE-metabolizing
enzyme. Also, L-NIL prevented HNE induced cell death at cytotoxic
levels.
Conclusions: Altogether, our ﬁndings support a beneﬁcial effect of L-NIL
in OA by preventing LPO process in NO-dependent and/or independent
mechanisms.
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INHIBITION OF WNT/b-CATENIN SIGNALING CAN BLOCK IL1b/TNFa
INDUCED CARTILAGE DEGRADATION IN A MURINE EX VIVO MODEL
E. Landman1, R. Miclea2, C. van Blitterswijk1, M. Karperien1. 1Univ. of
Twente, Enschede, Netherlands; 2Univ. Med. Ctr. Leiden, Leiden, Netherlands
Purpose: Osteoarthritis (OA) is a very common and disabling disease
that is characterized by progressive articular cartilage loss, synovial
inﬂammation and subchondral bone changes. Even though the primary
etiology of OA remains undetermined, it is believed that a disbalance
between anabolic and catabolic processes that normally occur in cartilage
underlies the pathophysiology. A disturbance of the Wnt/b-catenin sig-
naling pathway is believed to be involved in this. Conditional activation
of b-catenin in mice results in an OA-like articular destruction of articular
cartilage and it has been shown that mice, in which the Wnt antagonist
FRZb is knocked out, are more susceptible to chemically induced OA.
Therefore, we studied the effect of inhibition of the Wnt/b-catenin
signaling pathway on IL1b and TNFa induced cartilage degradation in
mouse fetal metatarsals. We have selected three small molecules that
inhibit binding of b-catenin to its transcription factors TCF and LEF.
Methods: We isolated the three middle metatarsals from fetal FVB
mouse embryos at day 17.5 of gestation. Metatarsals were cultured for an
equilibration period of 48 hours before treatment with IL1b/TNF and the
small molecules, which were added to the metatarsals simultaneously.
Metatarsals were treated for 1, 4 or 7 days for histology (n =2), for 1 or
4 days for gene expression analysis (pooled 5 metatarsals, n = 2) and for
7 days for glycosaminoglycan (GAG) quantiﬁcation (n =5). Pictures were
taken at different time points for morphometric analysis.
Results: Morphometric analysis of the metatarsals showed that the
longitudinal growth of the metatarsals is impaired by treatment with IL1b
and TNFa. In addition, the cytokines caused severe folding and shriveling
up of the metatarsals which was increasing over time due to cartilage
degradation. Addition of the small molecules prevented these catabolic
effects. Furthermore, they inhibited the loss of GAGs and collagen II from
the extracellular matrix induced by IL1b and TNFa.
Conclusions: In conclusion, we prove that inhibition of the binding of
b-catenin to its transcription factors TCF and LEF can prevent IL1b and
TNFa induced cartilage degradation in mouse fetal metatarsals. Since
IL1b plays an important role in cartilage degradation in OA, inhibition
b-catenin activity might be a new therapeutic option for OA.
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SALMON CALCITONIN PREVENTED CHONDROCYTE HYPERTROPHY
EX VIVO
P. Chen-An, K. Henriksen, M.A. Karsdal, A-C. Bay-Jensen. Nordic BioSci.
A/S, Herlev, Denmark
Purpose: Chondrocyte hypertrophy is a key event of the pathogenesis
of osteoarthritis (OA), which leads to cartilage calciﬁcation. To inhibit or
prevent the hypertrophy would contribute to inhibit or delay the onset
of early OA. Calcitonin is widely used as an anti-resorptive agent for
the treatment of osteoporosis. However, the application of calcitonin in
treatment of joint degenerative disease has likewise been investigated,
but is less understood. The effect of calcitonin on cartilage hypertrophy
and calciﬁcation is yet to be understood. The aim of our work was
to investigate the effect of salmon calcitonin (sCT) on hypertrophic
chondrocytes, in a well characterized and validated ex vivo model.
Methods: Full depth cartilage (FDC) explants (from superﬁcial to calciﬁed
cartilage) were isolated from bovine femoral condyle and hypertrophy
was induced by culture for 4 days with triiodo-L-thyronine (T3)
stimulation. Non-stimulated explants were cultured as control (W/O).
Doses of sCT ranged from 1nM to 100nM were added from day 0 to
day 4. Type X collagen (COL X) localization on hypertrophic chondrocytes
was analyzed by immunohistochemistry. Calcitonin receptor (CTR)
expression was evaluated by RT-PCR. Cartilage turnover was measured by
biochemical markers of type II collagen (COL II) formation (PIINP assay)
and degradation (CIIM assay). A sandwich ELISA assay – AGNx-II was
used for measuring aggreacan degradation. As markers of hypertrophic
chondrocytes, Indian hedgehog (IHH), COL X, alkaline phosphatase (ALP)
and matrix metallopeptidase 13 (MMP-13) were evaluated using RT-
PCR. Histological analysis was used for chondrocytes morphological
measurement.
Results: Hypertrophy was induced by 4 days stimulation with
T3. Hypertrophic chondrocytes expressed COL X, visualized by
immunohistochemistry as brown color around the cells. The induction
of hypertrophy led to a ~10 fold higher CTR mRNA expression
than W/O (p < 0.05). sCT increased COL II formation and decreased
aggreacan degradation dose-dependently, comparing with T3 induced
hypertrophy. In contrast, T3 induced signiﬁcant release of CIIM fragments
compared with W/O (p < 0.01). sCT showed a suppression effect on
COL II degradation, whereas the CIIM level still higher than control.
The induction of hypertrophy had signiﬁcant higher expression of
Ihh (p < 0.01), COL X (p < 0.001) and ALP (p < 0.001) compared with
control, where MMP-13 expression was also higher than control but
not signiﬁcantly. 1nM and 10nM sCT both suppressed the expression
of the four markers of hypertrophic chondrocytes, in which 10nM
inhibited the expression of Ihh, COL X and ALP signﬁciantly (p < 0.05). On
the contrary, 100nM increased the expression of the four hypertrophy
markers signiﬁcantly (p < 0.01). Chondrocytes morphology showed that
1nM and 10nM sCT treated explants had less hypertrophic chondrocytes,
where 100nM sCT had comparable hypertrophic chondrocytes compared
with T3 treated explants.
Conclusions: In our model, T3 induced hypertrophic chondrocytes at
day4. The expression of calcitonin receptor was highly upregulated
in hypertrophic chondrocytes compared the non-hypertrophic
chondrocytes. T3 induced hypertrophic chondrocytes had signiﬁcant
increased level of cartilage degradation. sCT suppressed expression of
markers of hypertrophic chondrocytes and cartilage degradation, in
which 10nM sCT is more promising. Our study demonstrated that
calcitonin treatment prevented chondrocyte hypertrophy in this ex vivo
model.
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TOWARD CARTILAGE DRUG DELIVERY: PEPTIDE CELL ASSOCIATION
VIA THE TAT-PTD IN PRIMARY HUMAN CHONDROCYTES
R.K. June1, D.C. Brinson2, M.K. Lotz2, S.F. Dowdy1. 1Univ. of California, San
Diego, La Jolla, CA, USA; 2The Scripps Res. Inst., La Jolla, CA, USA
Purpose: Delivery of bioactive molecules to articular chondrocytes is a
major challenge toward creating effective treatments for osteoarthritis.
Intra-articular delivery of standard therapeutics is limited by short
residence times because of diffusion to synovial capillary beds resulting
in active export from the joint. The TAT Peptide Transduction Domain
(PTD) is a cationic 9 amino acid peptide from the HIV TAT protein that has
been successfully used to deliver a variety of macromolecules (peptides,
proteins, siRNAs) to numerous cell types. The purpose of this study was
to determine if the TAT PTD could enable cell-association of peptides in
primary human chondrocytes from a wide variety of donors.
Methods: Rhodamine-labeled peptides were synthesized using solid-
phase peptide synthesis with Fmoc protection in 25mM scale on a
Symphony Quartet peptide synthesizer. All peptides were cleaved and
deprotected using a standard protocol (95% triﬂuoroacetic acid, 1%
water, 1% triisopropylsilane). Crude peptides were precipitated using cold
diethylether and puriﬁed using prep-scale reversed-phase HPLC with a
C18 column; purity was conﬁrmed by MALDI-TOF mass spectrometry
using the matrix a-CHCA. Primary human chondrocytes (n =6) were
harvested from human cadaveric tissue via enzymatic digestion and
grown in DMEM with 10% fetal calf serum. For experiments, 50,000
cells per well were plated in 12 well plates. Two days later cells were
washed with HBSS and treated with control or TAT-peptides (1.25, 2.5,
or 5mM) for 1 hour or left untreated. Following treatment, cells were
